All In Biotech

Drug Trial Radar · NCT06477926

A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants

A Phase 1 Relative Bioavailability and Food Effect Study of ABBV-668 Extended-Release Formulations

Last checked: Nov 19, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Jul 9, 2024

Primary completion

Sep 20, 2024

Study completion Sep 20, 2024

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jun 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objectives of this study are to assess safety and tolerability of the new ABBV-668 ER tablets, to assess the oral bioavailability of the ABBV-668 ER tablets relative to the ABBV-668 IR capsules, and to assess the pharmacokinetics of the ER tablets under fasting and fed conditions in healthy adults.

Conditions

  • Healthy Volunteers

Interventions

  • ABBV-668 IRDrug

    • Oral Capsule

  • ABBV-668 ERDrug

    • Oral Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Concentration (Cmax) of ABBV-668Time frame: Up to approximately 47 days
  2. Time to Cmax (Tmax) of ABBV-668Time frame: Up to approximately 47 days
  3. Terminal Phase Elimination Rate Constant (Beta) of ABBV-668Time frame: Up to approximately 47 days
  4. Terminal Phase Elimination Half-Life (t1/2) of ABBV-668Time frame: Up to approximately 47 days
  5. Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-668Time frame: Up to approximately 47 days
  6. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-688Time frame: Up to approximately 47 days
  7. Number of Participants With Adverse Events (AEs)Time frame: Up to Day 47

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Acpru /Id# 266960

    Grayslake, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.